TEVOGEN BIO HOLDINGS INC

NASDAQ: TVGN (Tevogen Bio Holdings Inc.)

Kemas kini terakhir: 30 Mar, 6:02AM

1.20

0.00 (0.00%)

Penutupan Terdahulu 1.20
Buka 1.22
Jumlah Dagangan 217,346
Purata Dagangan (3B) 2,097,001
Modal Pasaran 210,061,216
Harga / Pendapatan (P/E TTM) 3.43
Julat 52 Minggu
0.256 (-78%) — 4.78 (298%)
EPS Cair (TTM) -0.070
Nisbah Semasa (MRQ) 0.260
Aliran Tunai Operasi (OCF TTM) -12.00 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 9.82 M
Pulangan Atas Aset (ROA TTM) -746.67%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Tevogen Bio Holdings Inc. - -

AISkor Stockmoo

-1.3
Konsensus Penganalisis 0.5
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal -2.5
Purata -1.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
TVGN 210 M - 3.43 -
BNTX 22 B - - 1.00
LEGN 6 B - - 5.65
CNTA 1 B - - 4.84
BCAX 565 M - - 1.17
MAZE 397 M - 113.38 -

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (“CD8+ CTLs” or “CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 84.63%
% Dimiliki oleh Institusi 1.40%

Pemilikan

Nama Tarikh Syer Dipegang
China Universal Asset Management Co., Ltd. 31 Dec 2024 37,117
11.0011.0010.5010.5010.0010.009.509.509.009.00Harga Sasaran MedianQ1 '25Q1 '25
Julat 52 Minggu
0.256 (-78%) — 4.78 (298%)
Median 10.00 (733.33%)
Jumlah 1 Beli
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
D. Boral Capital 11 Mar 2025 10.00 (733.33%) Beli 1.07
04 Mar 2025 10.00 (733.33%) Beli 1.27

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
09 Apr 2025 Pengumuman Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
08 Apr 2025 Pengumuman Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
07 Apr 2025 Pengumuman Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
26 Mar 2025 Pengumuman Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
25 Mar 2025 Pengumuman Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
10 Mar 2025 Pengumuman Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
07 Mar 2025 Pengumuman Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
03 Mar 2025 Pengumuman Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
28 Feb 2025 Pengumuman Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
21 Feb 2025 Pengumuman Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
14 Feb 2025 Pengumuman Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
14 Feb 2025 Pengumuman Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
14 Feb 2025 Pengumuman Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
13 Feb 2025 Pengumuman Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
10 Feb 2025 Pengumuman Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
07 Feb 2025 Pengumuman Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
28 Jan 2025 Pengumuman Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
27 Jan 2025 Pengumuman Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
24 Jan 2025 Pengumuman Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
23 Jan 2025 Pengumuman Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
Papar semua
1.291.291.141.140.9980.9980.8540.8540.7100.710Apr 1Apr 1Apr 2Apr 2Apr 3Apr 3Apr 4Apr 4Apr 7Apr 7Apr 8Apr 8Apr 9Apr 9Apr 10Apr 10

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.1000.1000.0500.050-0.000-0.000-0.050-0.050-0.100-0.100MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda